Please login to the form below

Not currently logged in
Email:
Password:

antisense drugs

This page shows the latest antisense drugs news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

have focused on RNA and oligonucleotide-based drugs to switch off the activity of problem genes and gene-editing using CRISPR technology, rather than vector-based gene transfer. ... also working with Ionis on antisense drugs for a range of targets

Latest news

  • Despite FDA concerns, Akcea rare disease drug clears FDA panel Despite FDA concerns, Akcea rare disease drug clears FDA panel

    There are no approved treatments and drugs such as fibrates or niacin that can usually help control high triglycerides are ineffective, so the only management available is a strict, lifelong diet ... Thrombocytopenia is a recognised side effects with

  • Janssen partners with Isis on stomach conditions Janssen partners with Isis on stomach conditions

    The two companies will focus on developing so-called'antisense' drugs that bind to the genetic sequence of a faulty gene in order to treat autoimmune disorders that affect the gastrointestinal ... Kynamro, which was approved by the US FDA at the

  • Biogen Idec gets exclusive access to Isis' neurology R&D Biogen Idec gets exclusive access to Isis' neurology R&D

    Biogen Idec gets exclusive access to Isis' neurology R&D. Fourth deal in two years with antisense specialist. ... of up to $220m for antisense drugs developed under the collaboration plus royalties on any eventual sales.

  • Roche and Isis in $392m deal to research drugs for brain disorder Roche and Isis in $392m deal to research drugs for brain disorder

    Will develop antisense drugs for Huntington's disease. Roche is to partner with Isis Pharmaceuticals to research medicines for the Huntington's disease – a rare, genetic brain disorder for which there ... To complement this research, Roche will combine

  • Biogen Idec licenses antisense drugs from Isis in $630m deal Biogen Idec licenses antisense drugs from Isis in $630m deal

    Biogen Idec licenses antisense drugs from Isis in $630m deal. Gains neurological and neuromuscular disorder projects. ... Biogen Idec has signed its third licensing agreement with antisense specialist Isis Therapeutics in less than a year, paying $30m

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    510. Isis. Antisense drugs for CVS metabolic and renaldisease. 65. Mirati Therapeutics. ... Exclusive licence. 90. Isis. AZ. Addition to Dec 2012 collaboration to develop antisense drugs in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Strategic collaboration. 1, 000. Isis/ Janssen. Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes).

  • Pharma deals during January 2015 Pharma deals during January 2015

    A $35m payment went in an upfront to Isis as part of its $835m headline deal for a collaboration to discover and develop antisense drugs in autoimmune disorders in the GI ... tract. The deal includes options to license drugs arising from the various

  • Pharma deals during December 2012 Pharma deals during December 2012

    an upfront of $30m, to discover and co-develop antisense drugs to treat three neurological or neuromuscular disorders. ... 231. Isis / Biogen. Co-development and option to licence. Discovery / research of antisense drugs.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics